Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00350844 · ClinicalTrials.gov registry record · Phase 1

Hydroxyurea for Children and Young Adults With Sickle Cell Disease and Pulmonary Hypertension

A Phase 1 study, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.

Terminated
Registry status
Phase 1
Development phase
6
Enrollment target

NCT00350844 is a Phase 1 study that was terminated before completion, run by Ann & Robert H Lurie Children's Hospital of Chicago. The registered enrollment target is 6 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00350844, a Phase 1 study, was terminated before completion, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.

TERMINATED
Registry status
Phase 1
Development phase
6 participants
Enrollment target

Study Summary

The goal of this study is to test the hypothesis that hydroxyurea is effective for the specific treatment of secondary pulmonary hypertension found on screening in children and young adults with sickle cell disease.

Interventions

  • DRUG Hydroxyurea

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2006-07
Est. Completion 2008-06
Phase Phase 1

What the Registry Record Tells You About NCT00350844

The ClinicalTrials.gov registry entry for NCT00350844 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Hydroxyurea is the first listed.

NCT00350844 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00350844 about?

NCT00350844 is a clinical study titled "Hydroxyurea for Children and Young Adults With Sickle Cell Disease and Pulmonary Hypertension". The goal of this study is to test the hypothesis that hydroxyurea is effective for the specific treatment of secondary pulmonary hypertension found on screening in children and young adults with sickle cell disease.

What is the current status of trial NCT00350844?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2006-07. Estimated completion is 2008-06.

What interventions are being tested in trial NCT00350844?

The interventions under investigation include: Hydroxyurea (DRUG).

Who is sponsoring clinical trial NCT00350844?

This trial is sponsored by Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.